lurasidone   Click here for help

GtoPdb Ligand ID: 7461

Synonyms: Latuda® | SM-13496
Approved drug
lurasidone is an approved drug (FDA (2010), EMA (2014))
Compound class: Synthetic organic
Comment: Lurasidone is an atypical antipsychotic with activity at serotonin family receptors that are involved in learning and memory. It is devoid of the anticholinergic effects which are common with most other antipsychotics.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 0
Rotatable bonds 5
Topological polar surface area 84.99
Molecular weight 492.26
XLogP 5.2
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES O=C1N(CC2CCCCC2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)C2C1C1CCC2C1
Isomeric SMILES O=C1N(C[C@@H]2CCCC[C@H]2CN2CCN(CC2)c2nsc3c2cccc3)C(=O)[C@@H]2[C@H]1[C@H]1CC[C@@H]2C1
InChI InChI=1S/C28H36N4O2S/c33-27-24-18-9-10-19(15-18)25(24)28(34)32(27)17-21-6-2-1-5-20(21)16-30-11-13-31(14-12-30)26-22-7-3-4-8-23(22)35-29-26/h3-4,7-8,18-21,24-25H,1-2,5-6,9-17H2/t18-,19+,20-,21-,24+,25-/m0/s1
InChI Key PQXKDMSYBGKCJA-CVTJIBDQSA-N
Bioactivity Comments
We have been unable to find publicly available bioactivity data for this drug at the human D2-like receptors, so therefore these have not been tagged as the drug's primary target. However, in vivo rodent studies clearly show that the effects of this drug arise via antagonism of these receptors [1]. And, in addition, an in vivo study in marmosets shows preferential binding of lurasidone to dopamine D2/D3 receptors over 5-HT2A receptors [2].
Selectivity at GPCRs
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
5-HT7 receptor Primary target of this compound Hs Antagonist Antagonist 9.3 pKi - 1
⤷ pKi 9.3 (Ki 4.95x10-10 M) [1]
D2 receptor Rn Antagonist Antagonist 8.8 pKi - 1
⤷ pKi 8.8 (Ki 1.68x10-9 M) [1]
5-HT2A receptor Rn Antagonist Antagonist 8.7 pKi - 1
⤷ pKi 8.7 (Ki 2.03x10-9 M) [1]
5-HT1A receptor Rn Agonist Partial agonist 8.2 pKi - 1
⤷ pKi 8.2 (Ki 6.75x10-9 M) [1]
α2C-adrenoceptor Hs Antagonist Antagonist 7.3 – 8.0 pKi - 1,3
⤷ pKi 7.3 – 8.0 [1,3]
α2A-adrenoceptor Hs Antagonist Antagonist 6.7 – 7.4 pKi - 1,3
⤷ pKi 6.7 – 7.4 [1,3]